Global Novel Antiviral Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Novel Antiviral Drugs Market size is expected to reach USD 96.92 Billion in 2034 from USD 78.36 Billion (2025) growing at a CAGR of 2.39% during 2026-2034.

The novel antiviral drugs market is entering a pivotal expansion phase driven by emerging infectious diseases, viral mutations, and advances in molecular pharmacology. Future drug development will rely on high-throughput screening, AI-guided molecular modeling, and structure-based design to identify potent inhibitors of viral replication and immune evasion. Next-generation delivery systems-including nanoparticle carriers and targeted biologics-will optimize therapeutic efficacy while minimizing systemic toxicity.

Precision medicine approaches will further tailor antiviral therapies based on viral genotyping and host immune profiles, enabling individualized treatment regimens. Integrating AI-driven clinical trial simulations, predictive pharmacokinetics, and in silico toxicity assessments will reduce development timelines and accelerate market readiness. Combination therapies targeting multiple viral pathways will also emerge as standard practice to prevent resistance development and improve patient outcomes.

Sustainability and scalability in manufacturing processes, coupled with global regulatory harmonization, will facilitate rapid deployment during epidemic or pandemic scenarios. Future antiviral markets will be defined by innovative drug modalities, adaptive clinical protocols, and strategic collaborations between biopharmaceutical developers, research institutions, and digital health platforms-positioning novel antivirals as critical tools in proactive infectious disease management.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type Scope

Branded
Generics

By Drug Class Scope

DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others

By Distribution Channel Scope

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Application Scope

HIV
Hepatitis
Herpes
Influenza
Others

COMPANIES PROFILED

F HoffmannLa Roche Ltd, GSK plc, AbbVie Inc, Merck Co Inc, Johnson Johnson Services Inc, BristolMyers Squibb Company, Cipla Inc, Aurobindo Pharma, Sun Pharmaceutical Industries, Dr Reddys Laboratories Ltd
We can customise the report as per your requirements.

Product Code: VMR11214755

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY TYPE SCOPE 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Type Scope
4.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY DRUG CLASS SCOPE 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Drug Class Scope
5.2. DNA Polymerase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Reverse Transcriptase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Protease Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Neuraminidase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL SCOPE 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Distribution Channel Scope
6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY APPLICATION SCOPE 2022-2034 (USD MN)

7.1. Market Analysis, Insights and Forecast Application Scope
7.2. HIV Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.5. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY REGION 2022-2034(USD MN)

8.1. Regional Outlook
8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Type Scope
- 8.2.2 By Drug Class Scope
- 8.2.3 By Distribution Channel Scope
- 8.2.4 By Application Scope
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Type Scope
- 8.3.2 By Drug Class Scope
- 8.3.3 By Distribution Channel Scope
- 8.3.4 By Application Scope
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Type Scope
- 8.4.2 By Drug Class Scope
- 8.4.3 By Distribution Channel Scope
- 8.4.4 By Application Scope
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Type Scope
- 8.5.2 By Drug Class Scope
- 8.5.3 By Distribution Channel Scope
- 8.5.4 By Application Scope
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Type Scope
- 8.6.2 By Drug Class Scope
- 8.6.3 By Distribution Channel Scope
- 8.6.4 By Application Scope
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

9.1. Recent Developments
9.2. Company Categorization
9.3. Supply Chain & Channel Partners (based on availability)
9.4. Market Share & Positioning Analysis (based on availability)
9.5. Vendor Landscape (based on availability)
9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL NOVEL ANTIVIRAL DRUGS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Company Profiles
- 10.2.1 F. Hoffmann-La Roche Ltd
- 10.2.2 GSK Plc
- 10.2.3 AbbVie Inc
- 10.2.4 Merck & Co. Inc
- 10.2.5 Johnson & Johnson Services Inc
- 10.2.6 Bristol-Myers Squibb Company
- 10.2.7 Cipla Inc
- 10.2.8 Aurobindo Pharma
- 10.2.9 Sun Pharmaceutical Industries
- 10.2.10 Dr. Reddy'S Laboratories Ltd